1. Home
  2. DJT vs ZYME Comparison

DJT vs ZYME Comparison

Compare DJT & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Trump Media & Technology Group Corp.

DJT

Trump Media & Technology Group Corp.

N/A

Current Price

$9.14

Market Cap

2.1B

Sector

Technology

ML Signal

N/A

Logo Zymeworks Inc.

ZYME

Zymeworks Inc.

N/A

Current Price

$29.50

Market Cap

1.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DJT
ZYME
Founded
2021
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Programming Data Processing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
1.7B
IPO Year
2021
2022

Fundamental Metrics

Financial Performance
Metric
DJT
ZYME
Price
$9.14
$29.50
Analyst Decision
Strong Buy
Analyst Count
0
11
Target Price
N/A
$38.90
AVG Volume (30 Days)
3.8M
664.4K
Earning Date
05-08-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
33.33
EPS
N/A
N/A
Revenue
$3,682,600.00
$105,965,000.00
Revenue This Year
N/A
$183.10
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
1.76
38.87
52 Week Low
$6.96
$14.69
52 Week High
$17.97
$31.34

Technical Indicators

Market Signals
Indicator
DJT
ZYME
Relative Strength Index (RSI) 54.48 62.76
Support Level $7.95 $22.26
Resistance Level $9.94 N/A
Average True Range (ATR) 0.43 1.68
MACD 0.05 0.29
Stochastic Oscillator 68.88 75.16

Price Performance

Historical Comparison
DJT
ZYME

About DJT Trump Media & Technology Group Corp.

Trump Media & Technology Group Corp is a media and technology company rooted in social media, digital streaming, information technology infrastructure, and more. Its initial product launch will focus on its social media platform, Truth Social, which encourages an open, free, and honest conversation without discriminating against political ideology.

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Share on Social Networks: